Andrea Apolo: Several accruing Clinical Trials for patients with Small Cell Bladder Cancer
Andrea Apolo, Director of the Bladder Cancer and Genitourinary Tumors Multidisciplinary Clinic at the National Cancer Institute, posted on X:
“We have several accruing Clinical Trials for patients with Small Cell Bladder Cancer.
1. Lurbi +/- Avelumab LASER.
2. SG +/- Atezo SMART.
3. Cabozantinib + Nivolumab ICONIC.”
Andrea Apolo is the Chief of the Bladder Cancer Section of the Genitourinary Malignancies Branch and Director of the Bladder Cancer and Genitourinary Tumors Multidisciplinary Clinic at the National Cancer Institute (USA). Apolo received a 2011 National Institutes of Health Award of Merit, the 2014 Lasker Clinical Research Scholars Program Award, the 2018 National Cancer Institute’s Director’s Award for Clinical Science, the 2018 Advancing Cancer Treatment Award for leadership in genitourinary clinical trial patient access, and the 2020 Arthur S. Flemming Award for leaders who make an impact in public service.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023